title: Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity.
abstract: BACKGROUND
  High-dose-rate brachytherapy (HDR-BT) is an accepted part of treatment for endometrial carcinoma and is usually performed in 1-2 fractions per week using different total doses and doses per fraction. To reduce the overall treatment time, HDR-BT was administered with a 3-4 days/week schedule.
  
  
  METHODS
  From June 2003 to December 2008, 164 patients with stage I-IIIc endometrial carcinoma were treated with HDR-BT (4-5 Gy per fraction). The patients were divided into two groups; Group 1 (40/164 patients) was treated with HDR-BT alone (6 fractions; 4 fractions/week) and Group 2 (124/164 patients) was treated with both (External Beam Radiotherapy [EBRT] + HDR-BT: 3 fractions/week). Complications were analyzed using RTOG scores for rectum and bladder and the objective scores of LENT-SOMA for vaginal complications.
  
  
  RESULTS
  The mean followup was 48 months. In Group 1, 35 % of patients underwent treatment in ≤10 days and 65 % in >10 days. In Group 2, 53.2 % received treatment in ≤5 days and in 46.8 % in >5 days. Vaginal relapse was observed in only two patients (1.2 %), both having received adjuvant EBRT + HDR-BT. Acute vaginal toxicity appeared in 8.5 % and late vaginal toxicity in 20.7 % of patients with 13.4 % being G1, 6.7 % G2 and only 0.6 % being G4. No statistically significant differences were found in complications in either brachytherapy group regardless of the overall time.
  
  
  CONCLUSIONS
  In our series, three fractions given in 3-5/days after EBRT or six fractions in 10 days, is a safe regimen in terms of complications and local control.
authors.affiliation: Radiation Oncology Department, Gynecologic Oncology Unit, Hospital Clínic, Institute of Haematology and Oncology (ICMHO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Villarroel 170, 08036, Barcelona, Spain. ivalduvi@clinic.ub.es
authors.forename: I
authors.initials: I
authors.lastname: Valduvieco
authors.forename: Á
authors.initials: Á
authors.lastname: Rovirosa
authors.forename: A
authors.initials: A
authors.lastname: Herreros
authors.forename: I
authors.initials: I
authors.lastname: Romera
authors.forename: I
authors.initials: I
authors.lastname: Ríos
authors.forename: C
authors.initials: C
authors.lastname: Ascaso
authors.forename: A
authors.initials: A
authors.lastname: Sánchez-Reyes
authors.forename: M
authors.initials: M
authors.lastname: Arenas
authors.forename: J
authors.initials: J
authors.lastname: Pahisa
authors.forename: A
authors.initials: A
authors.lastname: Biete
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects*; D019583:Dose Fractionation, Radiation; D016889:Endometrial Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011184:Postoperative Period; D014621:Vagina / Q000473:pathology / Q000528:radiation effects*; D014625:Vaginal Neoplasms / Q000473:pathology / Q000517:prevention & control*